Doubled survival in metastatic lung cancer with combination therapy
Doubled survival in metastatic lung cancer with combination therapy
Combined immuno-chemotherapy improves survival and responses in metastatic lung cancer
Results from CheckMate-227 : Immune combination reaches PFS endpoint
Editor's Choice for February 2018
6-factor prognostic model for patients with advanced urothelial carcinoma
Comment: Urothelial cancer research from ASCO GU 2018
VinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis
Crizotinib for advanced papillary renal cell carcinoma with MET mutations or amplification
Neoadjuvant and adjuvant therapy in triple negative breast cancer
The DESKTOPIII trial in platinum-sensitive ovarian cancer
Developing drugs for personalised medicine
Why we are not ready for personalised medicine